Mind Medicine (MNMD) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MindMed has appointed Gregg A. Pratt, Ph.D., as the Chief Regulatory and Quality Assurance Officer to enhance their regulatory capabilities and expedite progress in launching Phase 3 studies for treatments targeting anxiety and depressive disorders. This move aims to leverage Dr. Pratt’s expertise in securing approvals for groundbreaking psychiatric drugs, including a novel schizophrenia treatment.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.